Aggressiveb Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1. Median progression-free survival in the HSCT group was significantly longer than in the non-HSCT group. 2. HSCT was associated with a slightly increased risk of serious adverse events, including graft-versus-host disease (59% vs. 44%, respectively). Evidence Rating Level: 2 (Good) Study Rundown: Advanced cutaneous T-cell lymphoma (CTCL) is a rare and aggressive form of

- Plenary Scientific Session to highlight Incyte-discovered novel anti-mutant CALR-targeted monoclonal antibody INCA033989 - Data from three of the Company's LIMBER studies evaluating ruxolitinib

Ian Flinn, MD, leads a roundtable discussion with Loretta Nastoupil, MD, and Amitkumar Mehta, MD

Ian Flinn, MD, leads a roundtable discussion with Loretta Nastoupil, MD, and Amitkumar Mehta, MD